Switch theme
Sign up to access all valuation multiples
Lunit Inc is a medical AI software company devoted to providing AI-powered total cancer care. Its products comprise of Lunit INSIGHT CXR, AI solution for Chest x-ray; Lunit INSIGHT MMG, AI solution for Mammography; Lunit SCOPE IO, AI-Powered Biomarker for Immuno-Oncology; and Lunit SCOPE PD-L1, AI Solution for PD-L1 Expression.
2013
272
LTM Revenue $48.1M
LTM EBITDA -$43.0M
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lunit has a last 12-month revenue (LTM) of $48.1M and a last 12-month EBITDA of -$43.0M.
In the most recent fiscal year, Lunit achieved revenue of $39.4M and an EBITDA of -$44.9M.
Lunit expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lunit valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $48.1M | XXX | $39.4M | XXX | XXX | XXX |
| Gross Profit | $48.1M | XXX | $39.4M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | -$43.0M | XXX | -$44.9M | XXX | XXX | XXX |
| EBITDA Margin | -89% | XXX | -114% | XXX | XXX | XXX |
| EBIT | -$49.1M | XXX | -$49.2M | XXX | XXX | XXX |
| EBIT Margin | -102% | XXX | -125% | XXX | XXX | XXX |
| Net Profit | -$49.5M | XXX | -$59.9M | XXX | XXX | XXX |
| Net Margin | -103% | XXX | -152% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $0.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lunit's stock price is KRW 47650 (or $35).
Lunit has current market cap of KRW 1.38T (or $1.0B), and EV of KRW 1.40T (or $1.0B).
See Lunit trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $1.0B | XXX | XXX | XXX | XXX | $-1.71 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lunit has market cap of $1.0B and EV of $1.0B.
Lunit's trades at 25.8x EV/Revenue multiple, and -22.6x EV/EBITDA.
Equity research analysts estimate Lunit's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lunit has a P/E ratio of -20.2x.
See valuation multiples for Lunit and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV/Revenue | 21.1x | XXX | 25.8x | XXX | XXX | XXX |
| EV/EBITDA | -23.6x | XXX | -22.6x | XXX | XXX | XXX |
| EV/EBIT | -20.7x | XXX | -20.7x | XXX | XXX | XXX |
| EV/Gross Profit | 21.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -20.2x | XXX | -16.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -19.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLunit's last 12 month revenue growth is 42%
Lunit's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Lunit's rule of 40 is -81% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lunit's rule of X is 16% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lunit and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | 42% | XXX | XXX | XXX |
| EBITDA Margin | -89% | XXX | -114% | XXX | XXX | XXX |
| EBITDA Growth | -17% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -81% | XXX | -72% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 16% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 40% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 50% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 225% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lunit acquired XXX companies to date.
Last acquisition by Lunit was XXXXXXXX, XXXXX XXXXX XXXXXX . Lunit acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lunit founded? | Lunit was founded in 2013. |
| Where is Lunit headquartered? | Lunit is headquartered in South Korea. |
| How many employees does Lunit have? | As of today, Lunit has 272 employees. |
| Who is the CEO of Lunit? | Lunit's CEO is Mr. Beom-Seok Seo. |
| Is Lunit publicy listed? | Yes, Lunit is a public company listed on KRX. |
| What is the stock symbol of Lunit? | Lunit trades under 328130 ticker. |
| When did Lunit go public? | Lunit went public in 2022. |
| Who are competitors of Lunit? | Similar companies to Lunit include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Lunit? | Lunit's current market cap is $1.0B |
| What is the current revenue of Lunit? | Lunit's last 12 months revenue is $48.1M. |
| What is the current revenue growth of Lunit? | Lunit revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Lunit? | Current revenue multiple of Lunit is 21.1x. |
| Is Lunit profitable? | Yes, Lunit is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lunit? | Lunit's last 12 months EBITDA is -$43.0M. |
| What is Lunit's EBITDA margin? | Lunit's last 12 months EBITDA margin is -89%. |
| What is the current EV/EBITDA multiple of Lunit? | Current EBITDA multiple of Lunit is -23.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
